My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 715

    1.

    Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.

    Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A.

    Diabetes Care. 2007 Jan;30(1):27-32.PMID: 17192328 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    [Pharmacological therapy of obesity]

    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

    G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian. PMID: 18773755 [PubMed - indexed for MEDLINE]Related articles

    3.

    X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.

    Diabetes Obes Metab. 2005 Nov;7(6):699-708.PMID: 16219013 [PubMed - indexed for MEDLINE]Related articles

    4.

    The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.

    Muls E, Kolanowski J, Scheen A, Van Gaal L; ObelHyx Study Group.

    Int J Obes Relat Metab Disord. 2001 Nov;25(11):1713-21.PMID: 11753595 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes.

    Shi YF, Pan CY, Hill J, Gao Y.

    Diabet Med. 2005 Dec;22(12):1737-43.PMID: 16401321 [PubMed - indexed for MEDLINE]Related articles

    6.

    Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.

    Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P.

    Diabetes Care. 2002 Jun;25(6):1033-41. Erratum in: Diabetes Care. 2003 Mar;26(3):971.. PMID: 12032111 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.

    Finer N, James WP, Kopelman PG, Lean ME, Williams G.

    Int J Obes Relat Metab Disord. 2000 Mar;24(3):306-13.PMID: 10757623 [PubMed - indexed for MEDLINE]Related articles

    8.

    Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

    Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB.

    JAMA. 1999 Jan 20;281(3):235-42. Erratum in: JAMA 1999 Apr 7;281(13):1174. PMID: 9918478 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.

    Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.

    Diabetes Obes Metab. 2003 May;5(3):180-8.PMID: 12681025 [PubMed - indexed for MEDLINE]Related articles

    10.

    Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

    Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M.

    Lancet. 1998 Jul 18;352(9123):167-72.PMID: 9683204 [PubMed - indexed for MEDLINE]Related articles

    11.

    The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study.

    Lindgärde F.

    J Intern Med. 2000 Sep;248(3):245-54.PMID: 10971792 [PubMed - indexed for MEDLINE]Related articles

    12.

    [Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients]

    Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar H, Krempf M; European Multicenter Orlistat Study Group.

    Ter Arkh. 2000;72(8):50-4. Russian. PMID: 11019429 [PubMed - indexed for MEDLINE]Related articles

    13.

    Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

    Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J.

    Diabetes Care. 1998 Aug;21(8):1288-94.PMID: 9702435 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.

    Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J.

    JAMA. 2005 Jun 15;293(23):2873-83. Erratum in: JAMA. 2005 Sep 28;294(12):1491. PMID: 15956632 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

    Torgerson JS, Hauptman J, Boldrin MN, Sjöström L.

    Diabetes Care. 2004 Jan;27(1):155-61. Erratum in: Diabetes Care. 2004 Mar;27(3):856. PMID: 14693982 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.

    Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JP, Sjöström L.

    Arch Intern Med. 2000 May 8;160(9):1321-6.PMID: 10809036 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.

    Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, Foreyt J, Aronne L, Klein S.

    Diabetes Care. 2002 Jul;25(7):1123-8. Erratum in: Diabetes Care. 2002 Sep;25(9):1671.. PMID: 12087008 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.

    Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G.

    Obes Res. 2000 Jan;8(1):49-61.PMID: 10678259 [PubMed - indexed for MEDLINE]Related articles

    19.

    A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.

    Berne C; Orlistat Swedish Type 2 diabetes Study Group.

    Diabet Med. 2005 May;22(5):612-8.PMID: 15842517 [PubMed - indexed for MEDLINE]Related articles

    20.

    Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study.

    Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S, Hougaard DM, Richelsen B.

    Eur J Endocrinol. 2008 Feb;158(2):179-87.PMID: 18230824 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity